Ratul Bhowmik

Ratul Bhowmik

Auto-generated profile, based on publicly available information

Ratul Bhowmik

Tampere University

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 August 2021 in Biosciences Biotechnology Research Asia
Verified
Journal Article
Open access
SSSounok Sengupta
Sounok Sengupta
RBRatul Bhowmik
Ratul Bhowmik
SASatarupa Acharjee
Satarupa Acharjee
SSSuchandra Sen
Suchandra Sen
The main objective of this present study was to analyze the anti-inflammatory activity of the compound 1- 3- [3-(substituted phenyl) prop-2-enoyl) phenyl thiourea against inflammation receptors Secretory Phospholipase A2 (sPLA2-X), Cyclooxygenase-2 (COX-2), Interleukin-1 Receptor-associated Kinase 4 (IRAK4), Tumor Necrosis Factor (TNF-alpha) and Inducible Nitric Oxide Synthase 4 using various in-silico techniques. The 3D structures of the receptors were retrieved from Protein Data Bank in PDB format. The ligand molecule was sketched in Chemdraw Ultra v 10.0. The proteins and the ligand molecule were then individually prepared for docking using AutoDock Tools. Docking was performed using AutoDock Vina. Swiss-ADME and Pre-ADMET web servers were used for ADME, drug-likeness, and toxicity analysis. The receptor showing the best binding affinity with our ligand molecule was further analyzed via Molecular Dynamics (MD) Simulations using iMODS web server. The docking results revealed that our ligand molecule showed the best binding affinity with receptor sPLA2-X. The ADME analysis results of our ligand molecule were also good. MD Simulations study showed good results with our ligand- sPLA2-X receptor docked complex. This study revealed that our ligand molecule is a significant inhibitor sPLA2-X and can be further used as a potential therapy against inflammatory disorders.

15 July 2024 in ChemRxiv
Verified
Preprint
Open access
PDF file
Ashok AspatwarAshok Aspatwar
Ashok Aspatwar
RNRanajit Nath
Ranajit Nath
RBRatul Bhowmik
Ratul Bhowmik
RJRajesh Jesudasan
Rajesh Jesudasan
This content was retracted at the authors' request to allow for corrections to the preprint. The study of artificial intelligence (AI), a multidimensional field, empowers machines with the ability to understand, reason, learn, and perform tasks autonomously. As a pivotal branch of computer science, AI excels in analyzing complex medical data and uncovering significant relationships for diverse diagnostic purposes. In neurology, innovative AI techniques have revolutionized diagnostics, management, and outcome prediction, opening new avenues for tackling neurological disorders. AI encompasses two key subsets: machine learning (ML) and deep learning (DL), which have gained immense popularity for predicting bioactivity, toxicology, physical and chemical properties, formulation quality, and drug-target interactions. The complexity of neurological diseases (ND) presents unique challenges in developing treatments for the central nervous system (CNS), given obstacles like the blood-brain barrier and high medication attrition rates. However, AI algorithms, leveraging vast datasets, efficiently analyze, interpret, and predict unknown facts, significantly accelerating CNS drug discovery. Deep learning architectures have furthered our understanding of AI's potential to address complex CNS disease issues, transforming the drug development landscape. This review delves into AI, ML, and their applications in advancing CNS drug and formulation development. It provides comprehensive, up-to-date insights on AI/ML advancements in neurology, emphasizing nanoparticle-based drug delivery systems. Additionally, the review covers ML algorithms' roles in de novo drug design, structure-based drug design, ligand-based drug design, absorption, distribution, metabolism, excretion, and toxicity (ADMET) prediction, and drug repurposing. Despite notable progress, significant challenges remain in enhancing AI's practical application in neurology. Overcoming these hurdles requires compiling extensive data and developing interpretable AI systems, paving the way for groundbreaking advancements in CNS drug development.

15 July 2024 in ChemRxiv
Verified
Preprint
Open access
PDF file
Ashok AspatwarAshok Aspatwar
Ashok Aspatwar
RNRanajit Nath
Ranajit Nath
RBRatul Bhowmik
Ratul Bhowmik
RJRajesh Jesudasan
Rajesh Jesudasan
This content was retracted at the authors' request to allow for corrections to the preprint. Nanotechnology has had a profound influence on human existence. Overcoming the many difficulties presented by various disorders, particularly neurological disorders (NDs), is a crucial approach. Various types of nanomaterials, including lipid nanoparticles, nanoliposomes, nano-micelles, polymer nanoparticles, and metal nanoparticles, along with different methods of transportation arrangements such as poly lactic o-glycolic acid, lactoferrin, and poly butyl cyanoacrylate, have the potential to greatly enhance the effectiveness, reduce the risk of negative outcomes, improve stability, and enhance the pharmacokinetics of many medications. Neurological disorders (NDs) are a subset of debilitating diseases that have a significant impact on a large population worldwide. Prior studies have shown that various formulations including nanotechnology, derived from a range of natural substances such as curcumin, quercetin, Ginkgo Biloba, and nigella sativa, significantly improve the well-being of persons with neurological disorders. The blood-brain barrier (BBB) is the primary obstacle preventing the passage of medications into the central nervous system (CNS), posing a challenge in the treatment of neurological disorders (NDs). . Engineered nanoparticles with altered physicochemical characteristics, ranging in size from 1 to 100 nm, can be utilized to enhance the effectiveness, cellular uptake, selective delivery, and distribution of specific particles to the brain. Nanoparticles derived from therapeutic plants and their constituents, known as phytomedicine from nano, have gained recognition for their abundant supply, ability to precisely target the brain, and reduced risk of adverse effects. These nanoparticles are increasingly important in the development of advanced neuro-therapeutics. This paper discusses the potential and ongoing advancements in using the combination of phytomedicine and nanotechnology for the treatment of neurological disorders. To summarize, herbal-based nanosystems, either alone or in combination with other drugs, demonstrate potential efficacy in the treatment of neurological disorders..

5 May 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
AMAjay Manaithiya
Ajay Manaithiya
RBRatul Bhowmik
Ratul Bhowmik
SASatarupa Acharjee
Satarupa Acharjee
SSSAMEER SHARMA
SAMEER SHARMA
SKSunil Kumar
Sunil Kumar
Ashok AspatwarAshok Aspatwar
Ashok Aspatwar
We developed a bio-cheminformatics method, exploring disease inhibition mechanisms using machine learning-enhanced quantitative structure-activity relationship (ML-QSAR) models and knowledge-driven neural networks. ML-QSAR models were developed using molecular fingerprint descriptors and the Random Forest algorithm to explore the chemical spaces of Chalcones inhibitors against diverse disease properties, including antifungal, anti-inflammatory, anticancer, antimicrobial, and antiviral effects. We generated and validated robust machine learning-based bioactivity prediction models (( https://ashspred.streamlit.app/ ) for the top genes. These models underwent ROC and applicability domain analysis, followed by molecular docking studies to elucidate the molecular mechanisms of the molecules. Through comprehensive neural network analysis, crucial genes such as AKT1, HSP90A1, SRC, and STAT3 were identified. The PubChem fingerprint-based model revealed key descriptors: PubchemFP521 for AKT1, PubchemFP180 for SRC, PubchemFP633 for HSP90, and PubchemFP145 and PubchemFP338 for STAT3, consistently contributing to bioactivity across targets. Notably, chalcone derivatives demonstrated significant bioactivity against target genes, with compound RA1 displaying a predictive pIC 50 value of 5.76 against HSP90A and strong binding affinities across other targets. Compounds RA5 to RA7 also exhibited high binding affinity scores comparable to or exceeding existing drugs. These findings emphasize the importance of knowledge-based neural network-based research for developing effective drugs against diverse disease properties. These interactions warrant further in vitro and in vivo investigations to elucidate their potential in rational drug design. The presented models provide valuable insights for inhibitor design and hold promise for drug development. Future research will prioritize investigating these molecules for mycobacterium tuberculosis , enhancing the comprehension of effectiveness in addressing infectious diseases.

5 May 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
AMAjay Manaithiya
Ajay Manaithiya
RBRatul Bhowmik
Ratul Bhowmik
AEAhmed El-Agrody
Ahmed El-Agrody
SSSAMEER SHARMA
SAMEER SHARMA
SDSusha Dinesh
Susha Dinesh
Ashok AspatwarAshok Aspatwar
Ashok Aspatwar
Traditional medicinal plants such as Zea mays show promising activities against diabetes and inflammation, yet their underlying molecular mechanisms remain elusive. Nevertheless, further elucidation of the molecular mechanism by which this medicinal plant exerts its anti-diabetic and anti-inflammatory effects and the relationship between its active constituents’ structure and activity is needed. Using a polypharmacology approach, this study identified metabolic pathways targeted by active phytochemicals of the medicinal plant Zea mays. Extensive network pharmacology and systems biology approaches, including protein-protein interaction network analysis, Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis, and gene functional enrichment studies, revealed that AKT1 is the key gene involved in the molecular mechanism of active phytochemicals involved in their antidiabetic and anti-inflammatory effects. A robust machine-learning-guided bioactivity prediction model-based web application (https://akt1-pred.streamlit.app/) against AKT1 was developed by implementing PubChem and substructure fingerprint molecular signatures. Further validation was performed by conducting ROC and applicability domain analysis, with subsequent molecular docking studies to understand the molecular mechanisms of the phytochemicals. The web application (Akt1-pred) predicted that delta-tocopherol, thiamine, and 9-ribosyl-trans-zeatin were the most active phytochemicals responsible for the antidiabetic and anti-inflammatory effects of the medicinal plant Zea mays, which was further supported by extensive molecular docking analysis and molecular dynamics simulation studies. These findings indicate a correlation between the structure of these molecules and their bioactivity, with some phytochemicals performing comparably or better than known FDA drugs. The results show that natural products could be very useful for medicine. They encourage more lab and animal studies and lay a strong base for future research on how these natural products can lead to new drugs.

3 May 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
AMAjay Manaithiya
Ajay Manaithiya
RBRatul Bhowmik
Ratul Bhowmik
RRRajarshi Ray
Rajarshi Ray
FCFabrizio Carta
Fabrizio Carta
CSClaudiu T Supuran
Claudiu T Supuran
Ashok AspatwarAshok Aspatwar
Ashok Aspatwar
This study demonstrated a novel bioinformatics pipeline to unravel a mechanistic understanding of the physiological and biochemical mechanism of Mycobacterium tuberculosis β-carbonic anhydrase 3, and its role in the key biological processes and metabolic pathways associated with its pathogenesis cycle. We initiated the study by constructing the 3D protein structure of β-CA3 from its sequence with the aid of homology modeling. To thoroughly investigate the essential properties of β-CA3, we further conducted computational genome sequencing, and proteomic analysis to reveal the key biological and structural information. The construction and development of a Python-based custom web server, SEQEclipse (https://seqeclipse.streamlit.app/), which is equipped with integrated work packages, was performed to study and gain insights into the sequence structure-function relationship of β-CA3 through analysis of its physicochemical properties, identification of phosphorylated sites and disordered regions, determination of the functional class of the sequence, BLAST and MSA analysis, determination of the protein-protein interaction mechanism, and development of an ab initio modeling strategy. We also employed a quantitative structural activity relationship (QSAR) model to understand the inhibition mechanism of small molecule modulators of β-CA3 concerning their diverse physiochemical properties. We further extended the QSAR strategy to mechanistic systems biology approach to unravel the key biological processes and metabolic pathways associated with the top β-CA3 modulators and their underlying mechanism of action to halt the pathogenesis cycle of Mtb. Our study outlines the biological significance of β-CA3 functionality and provides a mechanistic understanding of phenotype-based design of small molecule modulators as anti-TB drugs for future prospects. Highlights Homology modeling was applied to decode the intricate dual-domain architecture of β-CA3, which is crucial for pioneering targeted therapies against Mycobacterium tuberculosis. SEQEclipse, a Python-based web server, was developed to centralize bioinformatics analyses, enhancing the drug design workflow. Machine learning QSAR models were utilized to pinpoint potent compounds targeting β-CA3, with descriptors such as ‘nHeavyAtom’ Atsm1, Atsm2, ‘apol’, ‘SubFP287’, ‘SubFP184’, ‘SubFP214’, and ‘SubFP275, showing high correlation and interaction potential. Systems biology was used to illustrate how identified active and inactive compounds interfere with essential metabolic pathways in Mycobacterium tuberculosis, suggesting novel therapeutic approaches. The need for validation of computational findings to confirm the efficacy and safety of identified compounds has been emphasized.